In the last 6 years, an impressive impact of the highly active antiretroviral therapy (HAART) on survival and morbidity in HIV-1-infected individuals has been attained. However, their prolonged use may induce metabolic adverse effects such as lipodistrophy, hypertension, diabetes mellitus, osteopenia and hyperlipidemia. Recently, new strategies such as short-cycle structured intermittent therapy (SIT; 7 days without therapy followed by 7 days with HAART) have been suggested. We tested this strategy in seven (four women and three men; mean of age 39 of years) HIV-positive individuals, all of whom had CD4 ϩ T cell counts greater than 500 cells/mm 3 and undetectable plasma viral load for at least 2 years. Our results indicated no opportunistic diseases or CD4 cell count decrease over a mean follow-up of 26 months. No plasma viral replication was detected in five of seven cases. There was a decrease in triglyceride levels to normal range (not statistically significant), but no modification of cholesterol levels. Thus, we recommend a larger clinical trial to determine if SIT is cost effective in developing countries. 7 
INTRODUCTION I
N THE LAST 6 YEARS, with highly active antiretroviral therapy (HAART), Brazil has experienced a prolongation of survival, a decrease in the number of opportunistic infections, and an improvement in the quality of life of HIV-infected individuals. 1, 2 In 1993, a federal law determined that the antiretroviral medications should be released free of cost by public health providers for all Brazilians with HIV/AIDS based on local guidelines. The Ministry of Health, through the National Coordination of DST/Aids, 3 developed programs for monitoring laboratory tests (CD4 ϩ cell counts and viral load quantification) and distribution of the medications at the national level.
Mathematical models demonstrated that if the viral replication was totally suppressed, 72 years of treatment would be necessary for complete HIV eradication in the reservoirs. 4 In fact, despite HAART efficacy, with undetectable viral loads for many years, some viral replication persists, and the therapy should continue lifelong. 5 Thus, HIV/Aids is now characterized as a chronic disease that can be controlled in many, but prolonged HAART exposure may drive the appearance of collateral effects, such as lipid and bony alterations, anomalous corporal fat redistribution, as well as cardiac toxicity. 6 Because of this, treatment strategies that avoid constant use of these drugs are desirable. 7, 8 It has been demonstrated that short-cycle structured intermittent therapy (SIT; 7 days without therapy followed by 7 days with HAART) with a zidovudine, lamivudine, or stavudine plus efavirenz regimen maintained suppression of plasma HIV viremia. 9, 10 In this study, we determined the safety and effectiveness of the SIT regime in HIV-infected carriers in São Paulo.
MATERIALS AND METHODS

Patient
Seven patients were selected from 223 HIVinfected individuals who have been followed at the Secondary Immunodeficiencies, Dermatology Department at the HC-FMUSP. These patients on regular treatment with HAART for least 2 years, had undetectable plasma viral load (Ͻ 80 copies per milliliter) for at least 2 years, had T CD4 ϩ cell counts above 500 cells/mm 3 for at least 12 months, and had never developed opportunistic infections or neoplasia. The participants had support from nurses, nutritionists, and psychologists, as do all patients in follow-up, and the HC-FMUSP ethical board approved the protocol and written informed consent was obtained in all participants. The seven patients, four women and three men, with a mean of age of 39 years, were followed for 12-42 months, mean 26 months (Table 1) , and self-reported HIV infection by sexual transmission route. All antiretroviral drugs were suspended at the same time during the time off therapy. The adherence was evaluated by a simple questionnaire, as described elsewhere. 11 Analysis of variance for either for interpatient or intrapatient, variation involved nonparametric Mann-Whitney's test.
Methods
Blood was collected on the fifth day without therapy every 4 months for all evaluations. 
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Ȩ CD4 ϩ T-cell counts were done with commercial kits, and counted by FACS equipment (XL model, Coulter, USA). RNA viral load was determined using polymerase chain reaction (PCR) commercial kits (HIV monitor Roche Diagnostic, Hercules, CA), with a detection limit of 400 copies per milliliter. Visual reading was also performed, which may be able to detect a single viral copy in the computer software. Over 5000 copies per milliliter was considered to be viral rebound.
RESULTS
The SIT group maintained viremia suppression and CD4 ϩ T-cell counts did not decrease. Only case 3 showed side effects in the final months of the trial because of efavirenz, and was switched to another regimen. Two cases, 2 and 6, had blips in their plasma viral load during the follow-up, but these were below 5000 copies per milliliter (Table 2) . Visual observation in computer software showed no copies in the 5 cases with full suppression of plasma viral load, indicating probably less than 1 copy per milliliter. The triglycerides and cholesterol levels were not statistically different after SIT (ranging from 180 to 245 before SIT, mean 201 mg/dL; and ranging from 186 to 228, mean 206 mg/dL after SIT), but a clear decrease in the former (from 170 to 134 mg/dL) was noted (Table 3) .
DISCUSSION
After a mean of almost 2 years of follow-up, none of seven patients showed any progression of HIV disease on a 7-day SIT regimen. Although two patients showed blips in their plasma viral load, the CD4 ϩ T-cell counts were maintained during this time. In addition, there were no significant alterations in triglycerides or cholesterol levels. However, a decrease in the first was noted. 01  184  65  70  02  169  336  173  03  208  85  97  04  229  155  140  05  67  239  166  06  99  187  113  07  99  127  278  Mean  150  170  134 HAART, highly active antiretroviral therapy; SIT, structured intermittent therapy.
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The chronic and continuous use of antiretroviral (ART) drugs constitutes a considerable economic problem for the country. In 2003, approximately 150,000 people used ART daily in Brazil. The cost of this treatment is approximately 232 million American dollars, and it would be even more expensive if the country did not possess the control and domestic production of several anti-HIV drugs. 12 The SIT patients used half of the prescribed medication. In one study of patients in our clinic, 11 approximately 40%-50% of HIV-infected patients presented with viral loads below the detection limit and CD4 ϩ T-cell counts above 500 cells/mm 3 . HAART was recommended for these patients based upon national guidelines current at the time. New modifications have been made to the guidelines, and currently they probably would not be considered for initiation of therapy. 13 However, once begun, suspension of HAART is not usually recommended. Thus, a considerable number of patients still on therapy despite high CD4 counts and low viral load would be potential subjects for SIT, with a large savings on medication costs for the country.
Our data agree with other pilot studies of 7-day SIT cycles in highly selected subjects, 9, 10 since no decrease in CD4 ϩ T-cell count, rebound in the viral load, nor HIV disease progression were seen among our patients. However, a clear possibility of blips in the viral load may happen during the follow-up in some patients. 10 Finally, our data with longer followup and using local resources in a developing country adds support for larger clinical trails to access the feasibility of SIT strategy.
